Faculty Collaboration Database

Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 2008;58(2):111-25

Date

02/15/2008

Pubmed ID

18272835

DOI

10.3322/CA.2007.0012

Scopus ID

2-s2.0-42049114228 (requires institutional sign-in at Scopus site)   106 Citations

Abstract

Accurate disease staging of patients with pancreatic cancer is essential to divide patients into prognostic subgroups, to allow delivery of stage-specific therapies, and to facilitate meaningful discussions between physicians and patients regarding management and expected outcomes. The tumor-node-metastasis staging system of the American Joint Commission on Cancer has undergone significant revisions over the past 2 decades. In its current form, the system places an emphasis on preoperative clinical staging and facilitates division of patients with pancreatic cancer into 4 groups based on a determination of local resectability and the presence or absence of distant disease as determined on high-quality cross-sectional imaging. A modern understanding of local tumor factors that influence technical resectability is incorporated into the algorithm. In this review, we examine the American Joint Commission on Cancer staging system, describe the rationale for its use, and demonstrate how it is a clinically relevant tool for the staging and management of patients with pancreatic cancer.

Author List

Katz MH, Hwang R, Fleming JB, Evans DB

Author

Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adenocarcinoma
Algorithms
Humans
Lymph Nodes
Lymphatic Metastasis
Neoplasm Staging
Pancreatectomy
Pancreatic Neoplasms
Prognosis
Survival Rate
Tomography, X-Ray Computed